Bone Biologics Corp
Bone Biologics Corporation is a clinical-stage developer of orthobiologic products for spine fusion markets. The Company is focused on bone regeneration in lumbar spinal fusion using neural epidermal growth factor-like 1 protein (NELL-1) in combination with demineralized bone matrix (DBM), a demineralized bone matrix from the Musculoskeletal Transplant Foundation (MTF) Biologics. The combination NELL-1/DBM medical device is an osteopromotive recombinant protein that provides target specific control over bone regeneration. NELL-1 in combination with DBM. NELL-1, a proprietary skeletal-specific growth factor that is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying Bone Biologics' stock, anticipating significant future price growth.
Financial Health
Bone Biologics Corp is showing good financial stability with solid book value and cash flow.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring BBLG
3D-Bioprinted Tissues
These cutting-edge companies are building the future of medicine by printing living human tissues layer by layer. Selected by expert analysts, this collection represents one of healthcare's most promising frontiers with potential to revolutionize transplantation and drug development.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Early‑stage catalysts
Clinical data, regulatory milestones or partner deals could move the stock, though outcomes are uncertain and can go either way.
Volatility & liquidity
Small market cap often means larger price swings and limited trading volume; be prepared for rapid moves and difficulty exiting positions.
Funding & partnerships
Access to capital or strategic collaborations can extend development plans, but funding needs may dilute shareholders if new equity is issued.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
